8 results about "Obesity prevention" patented technology

Provided herein, in part, is a method of treating or preventing obesity or an obesity-related disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a small molecule inhibitor of an Activin receptor Type II.

One aspect of the present invention relates to: a conjugate comprising a peptide of a novel sequence and glycyrrhizin; and a pharmaceutical composition for preventing or treating obesity, the composition comprising the conjugate. The conjugate and composition comprising same according to one aspect were found to inhibit hypertrophy of fat cells, increase the cell membrane expression level of ATP-binding cassette transporter A1 (ABCA1), and reduce the secretion of tumor necrosis factor-α (TNF-α). In addition, the conjugate and composition comprising same were found to remain in a greater amount in the blood and have better pharmacokinetic properties than glycyrrhizin used by itself, and thus can be used in the obesity prevention and / or treatment market / industry.

The present invention relates to a crystalline form I represented by Formula 1, which may be characterized by XRD patterns, DSC profiles, and / or TGA profiles, a method for preparing the same, and a pharmaceutical composition comprising the same, useful for the treatment of prevention of obesity, diabetes, inflammation, or erectile dysfunction. (see formula 1) wherein R1 is C2-C5 alkyl.

The present invention provides a device and method for preventing obesity and regulating body weight using non-invasive blood glucose measurement, the device comprising: a sensing unit that generates lifestyle pattern biological information by detecting motion sensing information and body information; a storage unit that stores biological information, motion standard model information, blood glucose measurement information, and blood glucose measurement synthesis information; a blood glucose measurement unit that measures blood glucose of a user in real time by non-invasive blood glucose measurement to acquire blood glucose measurement information; a personal matching unit that compares the amount of blood glucose measured by the blood glucose measurement unit with blood glucose amount synthesis information stored in the storage unit according to an externally input or preset blood glucose level range and increase / decrease information; a blood glucose level processing unit that outputs a personal matching result in real time using a comparison result of the personal matching unit; and an output unit that outputs the personal matching result output from the blood glucose level processing unit to the outside so that the outside can recognize.

The compounds and methods of the present disclosure exhibit induce Ucp1 transcription, enhance of mitochondrial respiration, activate protein kinase A, increase lipolysis, and increase p38 MAPK phosphorylation in cells, particularly brown adipocytes and white adipocytes. They also protect primary cardiomyocytes against hypertrophy induced by adrenergic agonists. Such compounds and methods are useful in the treatment and prevention of conditions such as obesity and associated complex metabolic, endocrine, and hemodynamic changes, as well as related conditions as dyslipidemias, cardiovascular disease, and type 2 diabetes.

In this specification, compounds of formula I and their pharmaceutically acceptable salts (wherein R 1 , R 2 , R 3 , L 1 , T 1 , T 2 , T 3 , T 4 , t1, and t2 are as defined herein), their use as GIPR antagonists, pharmaceutical compositions containing such compounds and salts, and the use of such compounds and salts for treating or preventing, for example, obesity, weight gain, and / or T2DM are described. 【Chemical Formula 1】 TIFF2026516633000207.tif175168

The present application provides a compound shown in formula I, wherein R1, R2, R3 are defined in the specification. The compound shown in formula I of the present application can effectively inhibit MOGAT2 enzyme activity, and has a clinical application prospect for treating and / or preventing obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, high VLDL, high fatty acid, diabetes or arteriosclerosis.

The application discloses application of recombinant trichinella thioredoxin peroxidase 2 in preparation of medicines for improving and / or preventing obesity, and relates to the technical field of biological medicines.The application first discovers that recombinant trichinella thioredoxin peroxidase 2 (rTsTPX2) has a remarkable effect of improving obesity and related metabolic disorders.Compared with the prior art, the application expands the application range of rTsTPX2 from the known anti-parasitic vaccine use to the field of obesity and metabolic disease prevention and treatment, and provides a brand-new candidate molecule for obesity treatment.rTsTPX2 can effectively improve adipose tissue and systemic chronic low-grade inflammation by inhibiting the polarization of macrophages to pro-inflammatory M1 type and promoting M2 type polarization, thereby improving glycolipid metabolic disorders from a pathological root, and reducing the obesity phenotype, which is different from the action mode of traditional weight loss medicines that only inhibit appetite or reduce lipid absorption.